InterCure

InterCure Ltd. (NASDAQ:INCR) has shown resilience in its H1 2024 performance despite facing significant challenges, according to equity research by Pablo Zuanic of Zuanic & Associates. The company reported revenues of 126 million NIS ($33.97 million), surpassing the estimated 121 million NIS. ...

It was just three years ago that a broad swath of Israeli society, including former prime ministers, defense bigwigs and celebrities seemed to be enamored by the country's up-and-coming cannabis industry.  Former Prime Minister Ehud Barak was...

Former prime minister of Israel and InterCure chairman Ehud Barak at the company’s market open from their cultivation site in Israel The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga...

During Benzinga Cannabis Capital Conference, several leaders of various cannabis companies gathered to discuss the continuous expansion of the cannabis market outside the U.S.   The panel included: Alvaro Torres, CEO of Khiron Life Sciences (OTC: KHRNF), a vertically...

One of Israel’s largest cannabis companies, InterCure Ltd. (NASDAQ: INCR) began trading on the NASDAQ Global Market on Wednesday. InterCure is a vertically integrated medical cannabis operator with a focus on pharmaceutical-grade, GMP-certified branded products and branded product offerings...

InterCure LTd. (TASE: INCR), doing business as Canndoc, is poised to acquire medical cannabis brand Better Holdings. The Israeli cannabis company inked a letter of intent to purchase 100% of Cann Pharmaceutical Ltd.'s shares, including Better’s Israel-based operations and 50% of Cann'...